Zecotek Medical Systems Inc.

Zecotek Medical Systems Inc.

February 06, 2006 13:15 ET

Zecotek Medical Systems Inc.: Appointment of David Wynne to Board of Directors


The Company is pleased to announce the appointment of Mr. David Wynne to its Board of Directors.

Mr. Wynne has over twenty-five years experience in international business development, venture capital, finance and operations. He is currently a partner at Upstream Ventures, a venture capital firm in Singapore. He was previously founder, COO and Chief Business Officer at MerLion Pharmaceuticals, a Singapore-based drug discovery company which he helped found in 2001. Previously he was Senior Vice President and a Board representative of Transpac Capital, one of Asia's oldest and largest venture capital companies. Mr. Wynne has served on the Executive Board of the Singapore Venture Capital Association and is presently on the Executive Committee of the Singapore Biotech Association. Before entering the private sector he served as a senior diplomat for Canada in Korea, Japan and Singapore and in APEC where he served as Canada's representative to the APEC Budget and Administration Committee and as the Canadian Deputy Chair of the Economic Committee. He was a co-founder of the Canadian software company Greenbook, which produced one of the first hypertext authoring tools for the Internet. He earned a Bachelor of Arts degree from Concordia University, Montreal, Canada and a Master of Arts in Public Administration & Economics from Carleton University, Ottawa, Canada.

The Company welcomes Mr. Wynne to its Board of Directors due to his broad-based private sector and government experience. In addition, Mr. Wynne's extensive experience in Asia, where he currently still resides, will provide the Company with strategic advice on establishing itself in the Asian markets which is key to the Company's products, as well as on conducting business in Asia.
The Company has granted incentive stock options to Mr. Wynne to purchase 100,000 common shares of the Company, exercisable at a price of $0.72 for a period of 5 years. The issuance of the stock options is subject to regulatory approval.

Zecotek Medical Systems Inc. is a market driven, Research and Development bio-photonics company with laboratories and base at the University of British Columbia. ZMS focuses on the creation of advanced materials and integrated optoelectronic devices for high resolution medical imaging, optical precision surgery and biopharmaceutical research. ZMS grows by developing and acquiring Intellectual Property and technology know-how through a very thorough selection mechanism which involves industry leaders and constant interaction with major end-users. ZMS commercializes its technologies through strategic alliances with leading OEM manufacturers and distributors.

On Behalf of the Board,

DR. A. F. ZERROUK, Chairman & CEO

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Contact Information

  • Zecotek Medical Systems Inc.
    (604) 689-4200